INTELLIA THERAPEUTICS, INC. Stock-Based Compensation
INTELLIA THERAPEUTICS, INC. (NTLA) reported Stock-Based Compensation of $31.55 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $18.07M, a 17.98% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $13.48M, a 38.28% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $16.74M, a 57.75% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $19.60M, a 50.52% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $80.22M, a 48.00% decline from fiscal 2024.
- INTELLIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $154.27M, a 15.09% increase from fiscal 2023.
- INTELLIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $134.05M, a 46.66% increase from fiscal 2022.
- INTELLIA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $91.40M, a 94.43% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 8 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $18.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $31.55M 10-Q · filed 2026-08-06 | $48.29M derived: sum of 3 quarters · filed 2026-08-06 | $67.90M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $13.48M 10-Q · filed 2026-05-11 | $30.22M derived: sum of 2 quarters · filed 2026-05-11 | $49.82M derived: sum of 3 quarters · filed 2026-05-11 | $71.86M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $16.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $36.34M derived: sum of 2 quarters · filed 2026-02-26 | $58.38M derived: sum of 3 quarters · filed 2026-08-06 | $80.22M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $19.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $41.64M derived: sum of 2 quarters · filed 2026-08-06 | $63.48M 10-Q · filed 2025-11-06 | $103.10M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $22.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $43.88M 10-Q · filed 2026-08-06 | $83.49M derived: sum of 3 quarters · filed 2026-08-06 | $123.11M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $21.84M 10-Q · filed 2026-05-11 | $61.46M derived: sum of 2 quarters · filed 2026-05-11 | $101.08M derived: sum of 3 quarters · filed 2026-05-11 | $141.94M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $39.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $79.24M derived: sum of 2 quarters · filed 2026-02-26 | $120.10M derived: sum of 3 quarters · filed 2026-02-26 | $154.27M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $39.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $80.48M derived: sum of 2 quarters · filed 2025-11-06 | $114.66M 10-Q · filed 2025-11-06 | $149.70M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $40.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $75.04M 10-Q · filed 2025-08-07 | $110.08M derived: sum of 3 quarters · filed 2026-02-26 | $145.43M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $34.18M 10-Q · filed 2025-05-08 | $69.22M derived: sum of 2 quarters · filed 2026-02-26 | $104.57M derived: sum of 3 quarters · filed 2026-02-26 | $140.97M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $35.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $70.39M derived: sum of 2 quarters · filed 2026-02-26 | $106.80M derived: sum of 3 quarters · filed 2026-02-26 | $134.05M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $35.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $71.75M derived: sum of 2 quarters · filed 2024-11-07 | $99.01M 10-Q · filed 2024-11-07 | $123.63M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $36.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $63.66M 10-Q · filed 2024-08-08 | $88.28M derived: sum of 3 quarters · filed 2025-02-27 | $113.50M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $27.25M 10-Q · filed 2024-05-09 | $51.88M derived: sum of 2 quarters · filed 2025-02-27 | $77.10M derived: sum of 3 quarters · filed 2025-02-27 | $100.16M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $24.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $49.84M derived: sum of 2 quarters · filed 2025-02-27 | $72.91M derived: sum of 3 quarters · filed 2025-02-27 | $91.40M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $25.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $48.28M derived: sum of 2 quarters · filed 2023-11-09 | $66.77M 10-Q · filed 2023-11-09 | $81.33M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-06-30 | $23.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $41.56M 10-Q · filed 2023-08-03 | $56.12M derived: sum of 3 quarters · filed 2024-02-22 | $71.53M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-03-31 | $18.49M 10-Q · filed 2023-05-04 | $33.05M derived: sum of 2 quarters · filed 2024-02-22 | $48.46M derived: sum of 3 quarters · filed 2024-02-22 | $59.08M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2021-12-31 | $14.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $29.97M derived: sum of 2 quarters · filed 2024-02-22 | $40.59M derived: sum of 3 quarters · filed 2024-02-22 | $47.01M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $15.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $26.02M derived: sum of 2 quarters · filed 2022-11-03 | $32.45M 10-Q · filed 2022-11-03 | $38.03M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | $10.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $17.04M 10-Q · filed 2022-08-04 | $22.62M derived: sum of 3 quarters · filed 2023-02-23 | $28.02M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | $6.42M 10-Q · filed 2022-05-05 | $12.01M derived: sum of 2 quarters · filed 2023-02-23 | $17.41M derived: sum of 3 quarters · filed 2023-02-23 | $22.17M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $5.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $10.98M derived: sum of 2 quarters · filed 2023-02-23 | $15.75M derived: sum of 3 quarters · filed 2023-02-23 | $19.90M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $5.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $10.16M derived: sum of 2 quarters · filed 2021-11-04 | $14.32M 10-Q · filed 2021-11-04 | $17.34M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | $4.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $8.92M 10-Q · filed 2021-08-05 | $11.94M derived: sum of 3 quarters · filed 2022-02-24 | $15.02M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | $4.16M 10-Q · filed 2021-05-06 | $7.17M derived: sum of 2 quarters · filed 2022-02-24 | $10.25M derived: sum of 3 quarters · filed 2022-02-24 | $14.66M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | $3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $6.09M derived: sum of 2 quarters · filed 2022-02-24 | $10.50M derived: sum of 3 quarters · filed 2022-02-24 | $15.09M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $3.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $7.48M derived: sum of 2 quarters · filed 2020-11-05 | $12.07M 10-Q · filed 2020-11-05 | $15.66M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-06-30 | $4.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $9.00M 10-Q · filed 2020-08-06 | $12.58M derived: sum of 3 quarters · filed 2021-02-26 | $17.03M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-03-31 | $4.59M 10-Q · filed 2020-05-07 | $8.17M derived: sum of 2 quarters · filed 2021-02-26 | $12.63M derived: sum of 3 quarters · filed 2021-02-26 | $17.53M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2018-12-31 | $3.58M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $8.04M derived: sum of 2 quarters · filed 2021-02-26 | $12.94M derived: sum of 3 quarters · filed 2021-02-26 | $17.05M 10-K · filed 2021-02-26 | |
| 2018-09-30 | $4.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $9.36M derived: sum of 2 quarters · filed 2019-10-31 | $13.46M 10-Q · filed 2019-10-31 | $20.06M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | $4.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $9.01M 10-Q · filed 2019-08-01 | $15.60M derived: sum of 3 quarters · filed 2020-02-27 | $18.85M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-03-31 | $4.11M 10-Q · filed 2019-05-02 | $10.70M derived: sum of 2 quarters · filed 2020-02-27 | $13.95M derived: sum of 3 quarters · filed 2020-02-27 | $16.80M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2017-12-31 | $6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $9.84M derived: sum of 2 quarters · filed 2020-02-27 | $12.69M derived: sum of 3 quarters · filed 2020-02-27 | $15.32M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $3.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $6.10M derived: sum of 2 quarters · filed 2018-10-31 | $8.73M 10-Q · filed 2018-10-31 | $10.74M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | $2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $5.48M 10-Q · filed 2018-08-01 | $7.49M derived: sum of 3 quarters · filed 2019-02-27 | $9.55M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | $2.63M 10-Q · filed 2018-05-01 | $4.64M derived: sum of 2 quarters · filed 2019-02-27 | $6.70M derived: sum of 3 quarters · filed 2019-02-27 | $8.53M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $4.07M derived: sum of 2 quarters · filed 2019-02-27 | $5.90M derived: sum of 3 quarters · filed 2019-02-27 | $6.71M 10-K · filed 2019-02-27 | |
| 2016-09-30 | $2.06M 10-Q · filed 2016-11-01 | $3.89M derived: sum of 2 quarters · filed 2016-11-01 | $4.70M 10-Q · filed 2017-10-31 | $5.16M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2016-06-30 | $1.83M 10-Q · filed 2016-08-04 | $2.65M 10-Q · filed 2017-08-01 | $3.11M derived: sum of 3 quarters · filed 2018-03-14 | $3.69M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2016-03-31 | $812.00K 10-Q · filed 2017-05-02 | $1.27M derived: sum of 2 quarters · filed 2018-03-14 | $1.85M derived: sum of 3 quarters · filed 2018-03-14 | $2.00M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2015-12-31 | $463.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $1.04M derived: sum of 2 quarters · filed 2018-03-14 | $1.19M derived: sum of 3 quarters · filed 2018-03-14 | $1.31M 10-K · filed 2018-03-14 | |
| 2015-09-30 | $579.00K 10-Q · filed 2016-11-01 | $730.00K derived: sum of 2 quarters · filed 2016-11-01 | $845.00K 10-Q · filed 2016-11-01 | ||
| 2015-06-30 | $151.00K 10-Q · filed 2016-08-04 | $266.00K 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | $115.00K 10-Q · filed 2016-06-03 | ||||
| 2014-12-31 | $308.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |